Marco Cicardi.

During the period of the scholarly study, two patients who presented to the same study site at the same time were given the wrong study drug: one patient randomly assigned to receive placebo instead received ecallantide, and something patient randomly assigned to receive ecallantide instead received placebo . One patient in the ecallantide group was dropped to follow-up after the day 7 visit. Outcome Measures At 4 hours after study-drug administration, the median treatment outcome score was 50.0 for the ecallantide-treated group and 0.0 for the placebo-treated group .50 to 0.00 to 0.00) in the placebo group .A new finding in liver antifibrinolytics and transplantation? Orthotopic liver transplantation is associated with heavy bleeding and considerable transfusion requirements. There are several reasons for this heavy bleeding in OLT. Hemostatic abnormalities stay a major cause. This study, performed by a team led by Professor Wang Xuehao, is to be released in the March 7, 2008 issue of the World Journal of Gastroenterology. Aprotinin, a serine protease inhibitor, can be used increasingly frequently in surgeries during operations such as cardiac liver and surgery transplantation to reduce bleeding and transfusion .We performed a meta-analysis to review the effect of aprotinin found in OLT on the intraoperative dependence on blood items and the postoperative outcomes.